Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATP4A | P20648 | 14/20 | 0.49 |
| ▸ | ATP4B | P51164 | 14/20 | 0.49 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.49 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.49 |
| ▸ | SLC22A2 | O15244 | 1/20 | 0.49 |
| ▸ | DDAH1 | O94760 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 1/20 | 0.49 |
| ▸ | HPGD | P15428 | 1/20 | 0.49 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.49 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.49 |
| ▸ | FASN | P49327 | 1/20 | 0.49 |
| ▸ | SLC47A2 | Q86VL8 | 1/20 | 0.49 |
| ▸ | SLC47A1 | Q96FL8 | 1/20 | 0.49 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.49 |
| ▸ | ATP1A1 | P05023 | 7/20 | 0.42 |
| ▸ | ATP1B1 | P05026 | 7/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27990381 | 0.88 | RUNX1 (0.52) | ATP4AATP4BCYP2C9CYP3A4KDM4E | |
| SCHEMBL27990358 | 0.80 | ATP4A (0.47) | ATP4AATP4BCYP2C9CYP3A4KDM4E | |
| SCHEMBL6359051 | 0.75 | ATP4A (0.58) | ATP4AATP4BCYP2C9CYP3A4KDM4E | |
| SCHEMBL23988389 | 0.74 | ATP4A (0.58) | ATP4AATP4BCYP2C9CYP3A4KDM4E | |
| SCHEMBL28087573 | 0.74 | ATP4A (0.50) | ATP4AATP4BCYP2C9CYP3A4KDM4E | |
| SCHEMBL4268582 | 0.74 | ATP4A (0.48) | ATP4AATP4BCYP2C9CYP3A4KDM4E | |
| SCHEMBL538298 | 0.73 | ATP4A (0.56) | ATP4AATP4BCYP2C9CYP3A4KDM4E | |
| SCHEMBL28580711 | 0.73 | ATP4A (0.47) | ATP4AATP4BCYP2C9CYP3A4KDM4E | |
| SCHEMBL30102856 | 0.73 | ATP4A (0.56) | ATP4AATP4BCYP2C9CYP3A4KDM4E | |
| SCHEMBL537800 | 0.72 | ATP4A (0.55) | ATP4AATP4BCYP2C9CYP3A4KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117562898-A | Oral formulations with omeprazole or pantoprazole | 西姆莱斯有限公司 | 2024-02-20 | — | — | CN | disclosed |
| US-20190240187-A1 | ORAL PREPARATIONS WITH OMEPRAZOLE OR PANTOPRAZOLE | SYMRISE AG (DE) | 2019-08-08 | — | — | US | disclosed |
| EP-3380085-A1 | ORAL PREPARATIONS WITH OMEPRAZOLE OR PANTOPRAZOLE | Symrise AG (DE) | 2018-10-03 | — | — | EP | disclosed |
| CN-108472262-A | Oral formulations with omeprazole or pantoprazole | 西姆莱斯有限公司 | 2018-08-31 | — | — | CN | disclosed |
| CN-103110592-B | Freeze-drying composition for injection and preparation method thereof | ZHEJIANG ZHENYUAN PHARMACEUTICAL CO LTD | 2015-02-04 | — | — | CN | disclosed |
| CN-104114169-A | Combination of CRTH2 antagonist and a proton pump inhibitor for the treatment of eosinophilic esophagitis | ATOPIX THERAPEUTICS LTD | 2014-10-22 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190240187-A1 | ORAL PREPARATIONS WITH OMEPRAZOLE OR PANTOPRAZOLE | PPIP5K2, CYP8B1, CYP3A43 | ATP4A 1747/4885ATP4B 525/4885CYP2C9 74/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.